Human Insulin market

1
Human Insulin Market Trends, Size, Share,
Demands, Overview, Growth, Revenue and Forecast
to 2030
sales_at_delvens.com www.delvens.com
2
Sternal Closure Systems Market Trends Forecast
Till 2030
Human Insulin Market, by product type
(traditional human insulins, basal or long-acting
insulins, bolus or fast-acting insulins, insulin
combinations, and biosimilar insulins), Drugs
(Biologics, Biosimilars), Brands (Lantus,
NovoRapid, Humalog), Delivery Devices (Pens, Pen
Needles, Syringes) Application (Type 1 Diabetes,
Type 2 Diabetes) and region (North America,
Europe, Asia-Pacific, Middle East and Africa and
South America).
Request For Free Sample Report
https//www.delvens.com/get-free-sample/human-insu
lin-market
sales_at_delvens.com
www.delvens.com
3
Market Overview
Human Insulin or Insulin is a hormone produced in
the human pancreas that regulates the amount of
glucose (sugar) in the bloodstream and the
metabolism of fats, proteins and carbohydrates in
the human body. Insulin is available in different
strengths the most common is U-100, which is
used as a dietary and exercise supplement to
improve glucose balance in children and
adults. The growth of the global market is
attributed to key factors such as increasing
demand for human insulin analogues and affordable
reimbursements. Technological innovations in
human insulin delivery devices are also boosting
the market. For example, in August 2020, the US
FDA approved the MiniMed 770G, an innovative
diabetes management device. This device
automatically monitors glucose levels and
delivers the correct basal insulin doses to
pediatric patients with type 1 diabetes with
minimal client (caregiver) input. Purchase
this Report https//www.delvens.com/checkout/huma
n-insulin-market
sales_at_delvens.com
www.delvens.com
4
Market Overview
The growth of the global market is attributed to
key factors such as increasing demand for human
insulin analogues and affordable reimbursements.
Technological innovations in human insulin
delivery devices are also boosting the market.
For example, in August 2020, the US FDA approved
the MiniMed 770G, an innovative diabetes
management device. This device automatically
monitors glucose levels and delivers the correct
basal insulin doses to pediatric patients with
type 1 diabetes with minimal client (caregiver)
input. The COVID-19 pandemic has significantly
affected the human insulin drug market. Patients
with type 1 diabetes were more affected during
Covid-19. Diabetics have a weak immune system, so
in case of COVID-19, the immune system weakens
very quickly. Diabetics are more likely to
develop serious complications than the general
population. In the midst of the pandemic, there
have been delays and disruptions in the supply of
medicines due to strategies designed to contain
the spread of SARS-CoV-2. In addition, hospitals
reported a decrease in insulin prescriptions.
However, in several countries, the impact of
COVID-19 decreased after the second quarter of
2021, helping the market to pull back.
sales_at_delvens.com
www.delvens.com
5
Key Findings
The Human Insulin market is segmented into
various segments such product type, brands,
delivery devices, application, drugs and
region By product, the human insulin market is
divided into two main segments drugs and dosing
devices. The human insulin drug segment is
expected to account for the largest share of the
global market by product in 2022. The
application segment is further bifurcated into
type-1 and type-2 diabetes. The largest segment
by application is type 1 diabetes mellitus, due
to the high insulin dependency of these patients.
It is a more severe condition than type 2
diabetes.
sales_at_delvens.com
www.delvens.com
6
Key Findings
By product type, the human insulin device market
is divided into three segments pens, pen needles
and syringes. The pen segment is expected to
account for the largest market share in 2022 it
will be the fastest growing segment in the next
five years The market is also divided into
various regions such as North America, Europe,
Asia-Pacific, South America, and Middle East and
Africa. North America is estimated to account for
the largest market share during the forecast
period. Inquire Before Buying
https//www.delvens.com/Inquire-before-buying/huma
n-insulin-market
sales_at_delvens.com
www.delvens.com
7
Competitive Landscape

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• Pfizer Inc.
• Biocon Ltd
• Wockhardt
• Boehringer Ingelheim International GmbH
• Julphar
• United Laboratories International Holdings Limited

• Tonghua Dongbao Pharmaceutical Co. Ltd.
• Exir
• Sedico
• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• Oramed
• Adocia
• Merck co. Inc

sales_at_delvens.com
www.delvens.com
8
Recent Developments
November 2022 The U.S. Food and Drug
Administration approved Tzield (teplizumab-mzwv)
injection to delay the onset of stage 3 type-1
diabetics and pediatric patients 8 years of age
and older who were stage 2 type-1 diabetics.
May 2022 The FDA approved Lillys new
medication Mounjaro (also known as tirzepatide)
for type-2 diabetes management in addition to
diet and exercise. This first-in-class medication
showed improvement in glucose levels and also
dramatically improved weight in clinical trials.
sales_at_delvens.com
www.delvens.com
9
Contact Information
About Us Delvens is a strategic advisory and
consulting company headquartered in New Delhi,
India. The company holds expertise in providing
syndicated research reports, customized research
reports and consulting services. Delvens
qualitative and quantitative data is highly
utilized by each level from niche to major
markets, serving more than 1K prominent companies
by assuring to provide the information on
country, regional and global business
environment. We have a database for more than 45
industries in more than 115 major countries
globally. Contact Us 44-20-3290-6466 1
214-377-1144 sales_at_delvens.com
sales_at_delvens.com
www.delvens.com